Article
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bone marrow transplantation - 1 Aug 2008
Bacher U, Zander A R, Haferlach T, Schnittger S, Fehse B, Kröger N
Abstract excerpt
Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the minimal residual disease, for example, by PCR or immunophenotyping gain increasing importance in the post transplantation period as basis for improved and earlier therapeutic interventions in impending relapse. Recent markers such as the NPM1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.